Cellnovo Chooses BGM’s ‘No. 1’ Over JNJ For Diabetes Management System
This article was originally published in Clinica
Cellnovo is integrating Roche’s Accu-Chek blood glucose monitoring platform into the latest version of its mobile, all-in-one diabetes management system. The Swiss drug and diagnostics giant’s BGM technology will replace Johnson & Johnson’s LifeScan OneTouch Vita which Cellnovo has been using until now.
You may also be interested in...
Cellnovo has signed a commercial license agreement with digital health firm TypeZero to integrate its artificial pancreas software technology into Cellnovo’s digitally connected insulin patch pump. The integrated product is expected to launch in 2018.
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.